Human prostate cell lines in cancer treatment

Details Human prostate cell lines in cancer treatment Human prostate cell lines in cancer treatment

2004-07-23

2008-10-21

Canella, Karen A (Department: 1643)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Cancer cell or component thereof

C424S572000, C424S573000

Reexamination Certificate

active

07438922

ABSTRACT:
Combinations of cell lines are provided for allogeneic immunotherapy agents in the treatment of cancer. Cancer vaccines generally have been limited to the use of cells that contain at least some tumor specific antigens (“TSAs”) and/or tumor associated antigens (“TAAs”) having shared identity with antigens in a targeted tumor. In such cases, tumor cells often are utilized as a starting point on the premise that only tumor cells will contain TSAs or TAAs or relevance, and the tissue origins of the cells are matched to the tumor site in patients. A primary aspect of the invention is the use of immortalized normal, non-malignant cells, in combination with primary and/or metastatic tumor cells, as the basis of an allogeneic cell cancer vaccine. Normal cells do not posses TSAs or relevant concentrations of TAAs and hence it is surprising that normal cells are effective as anti-cancer vaccines when administered in combination with primary and/or metastatic tumor cells. More surprisingly, a three way combination of cells obtained from metastasized cells, non metastasized tumor and cells from a normal cell line provided good therapy. For prostate cancer, for example, a vaccine may be based on one or a combination of different immortalized normal cell lines derived from the prostate according to parameters described herein. The cell lines may be lethally irradiated with, for example, gamma irradiation at 50-300 Gy to ensure that they are replication incompetent prior to use.

REFERENCES:
patent: 5804443 (1998-09-01), Bernofsky
patent: 6699483 (2004-03-01), Dalgleish et al.
patent: 6972128 (2005-12-01), Dalgleish et al.
patent: WO93/06867 (1993-04-01), None
patent: WO 95/29704 (1995-11-01), None
patent: WO 97/18296 (1997-05-01), None
patent: WO97/24132 (1997-07-01), None
patent: WO97/28255 (1997-08-01), None
patent: WO 98/16238 (1998-04-01), None
patent: WO 99/19462 (1999-04-01), None
patent: WO 00/04918 (2000-02-01), None
patent: WO 0033869 (2000-06-01), None
patent: WO 0033870 (2000-06-01), None
patent: WO 00/71155 (2000-11-01), None
patent: WO 0175073 (2001-10-01), None
Corbel MJ Dev. Biol. Stand. 87:113-124, 1996, Abstract only enclosed.
Usmani BA et al. Clinical Science 103(Suppl. 48): 314S-317S, 2002.
Clark (Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, 1993, p. 1).
Ablin, J. Cancer Res. Clin. Oncol. 123: 583-594 (1997).
Berthon, Intl J Oncology, 6(2): 333-343 (1995).
Boon, Adv Can Res 58: 177-210 (1992).
Brenner et al., Journal of Urology, pp. 1575-1579 (1995) (abstract only).
Bright et al., Cancer Research (57)(1): 995-1002 (1997).
Carducci et al., Journal of Clinical Oncology 21(4): 679-689 (2003).
Curti, Crit. Rev, in Oncology/Hematology 14:29-39 (1993).
D'Amico et al., American Society of Clinical Oncology, Abstract No. 4506 (2004).
Dermer, Bio/Technology 12:320 (1994).
Diederichsen et al., Oncology Reports 5: 823-826 (1998).
Dillman et al. Cancer Biotherapy & Radiopharmaceuticals 15(2): 161-168 (2000).
Drexler et al., Leukemia and Lymphoma 9:1-25 (1993).
Eaton et al., BJU International 89: 19-26 (2002).
Embleton et al., Immunol Ser 23:181-207 (1984).
Engel et al., Scand. J. Immunol. 45: 463-470 (1997).
Esparaza et al., J. of Immnology 131(5): 2117-2121 (1983).
Fenton et al., J. of Immunotherapy 19(5): 364-374 1996).
Fogel et al., J. Natl. Cancer Inst. 62(3):585-588 (1979).
Freshney, Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., New York, p. 4 (1983).
Gorelik et al., Journal of Supramolecular Structure 12: 385-402 (1979) (abstract only).
Gura, Science 278:1041-1042 (1997).
Hartwell et al., Science 278:1064-1068 (1997).
Hrouda et al., BJU International 86: 742-748 (2000).
Hsu, Tissue Culture Methods and Applications, Kruse and Patterson, Eds., Academic Press, NY, pp. 764767 (1973).
Jåger et al., Int. J. Cancer 71: 142-147 (1997).
Jain, Sci. Am. 271:58-65 (1994).
Kayaga et al., Gene Therapy 6: 1475-1481 (1999).
Kusumoto et al., Cancer Immunol Immunother 50: 373-381 (2001).
Kylstra et al., Proceedings of the AACR, vol. 44, 2nded., Abstract No. 5396 (2003).
Lehner et al., Cancer Immunol Immunother 32: 173-178 (1990).
Maitland et al., Radiation Research 155: 133-142 (2001).
Marble, Cancer Weekly Plus, p. 4(2) (1997).
Moran, American Medical News 42, 39, 23 (1999).
Nelson et al., American Society of Clinical Oncology, Abstract No. 4554 (2004).
Schreiber et al., Human Gene Therapy 10: 983-993 (1999).
Small et al., Journal of Clinical Oncology 18(23): 3894-3903 (2000).
Tamura et al., Science 278: 117-120 (1997).
Triest et al., Clinical Cancer Res. 4(8): 2009-14 (1998).
Vermorken et al., The Lancet 353: 345-350 (1999).
Vieweg et al., Cancer Research 54: 1760-1765 (1994).
Volpe, Cancer Genet Cytogenet 34: 125-134 (1988).
Wu et al., Intl J cancer, 77(6): 887-94 (1998).
Bellone et al., Immunology Today 20(10): 456-461 (1999).
Olumi et al., Cancer Research 58: 4525-4530 (1998).
Thraves et al., Pub. No. US 2003/0185808 (Oct. 2, 2003).
Tjoa et al., The Prostate 27: 63-69 (1995).
Zhau et al., Proc. Natl. Acad. Sci. USA 93: 15152-15157 (1996).
Weiner, Seminars Oncology 26(4)(12): 41-50 (1999).

Affiliated with

Also associated with

Rating

Human prostate cell lines in cancer treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human prostate cell lines in cancer treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human prostate cell lines in cancer treatment will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4013056